Valeant (VRX) volatility flat into upgrade to Overweight at Morgan Stanley
Tweet
Share
E-mail
Valeant Pharma (NYSE: VRX) August and September call option implied volatility of 62 compares to its 52-week range of 33 to 173 into Morgan Stanley’s upgrade to Overweight and raising its price target to $42 from $33.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AbbVie (ABBV) April weekly option implied volatility into quarter results
- GE Vernova (GEV) June 130 puts active
- ExxonMobil (XOM) April weekly option implied volatility into quarter results
Create E-mail Alert Related Categories
Options, Trader TalkRelated Entities
Morgan Stanley, OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
